NDAORALSUSPENSION
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CARAFATE (sucralfate) by AbbVie is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. First approved in 1993.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAFATE (sucralfate) is an oral aluminum complex suspension approved in 1993 for duodenal ulcer healing. It works through local gastrointestinal action by forming an ulcer-adherent protective complex that shields the ulcer site from acid, pepsin, and bile salts. Sucralfate is minimally absorbed systemically and excreted primarily in urine.
$0.002BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims (5,048 in 2023), indicating a contracted team focused on defensive strategies rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Pharmacologic Class:
Aluminum Complex
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CARAFATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.